Blog

  • 2025 United States Grand Prix – McLaren Sprint Qualifying Report

    2025 United States Grand Prix – McLaren Sprint Qualifying Report

    “A positive start to the weekend in Austin with a relatively comprehensive representation of the field. Today’s sessions confirm that our main competitor has improved their car and continues to provide close competition at the different types of…

    Continue Reading

  • Why India’s Diwali gold rush is different this year

    Why India’s Diwali gold rush is different this year

    Anahita SachdevDelhi and

    Nikhil InamdarMumbai

    Getty Images A woman looks into the mirror as she tries on an earring in a jewellery shop in India. Getty Images

    More Indians are choosing buying gold for investment purposes this festive season

    Ahead of the Hindu festival of Diwali, the jewellery market in Indian capital Delhi’s vibrant Lajpat Nagar neighbourhood is teeming with crowds.

    Shops have stayed open even on holidays, and at dusk, dozens of cars line up the streets as a string of flashy signboards beckon shoppers into the flower-adorned stores.

    Soaring gold prices – which have topped $1,440 (£1,081) for 10g – may have slightly dented demand for jewellery in the world’s second largest market for the yellow metal this year, but Indians are not willing to entirely give up on their penchant for gold yet.

    Diwali, along with Dhanteras – a smaller festival that falls on Saturday this year – are believed to be auspicious occasions to buy precious metal, with hundreds of thousands of Indians flocking the markets to buy gold and silver coins, bars and jewellery, which they believe bring wealth and luck.

    Skyrocketing prices have created FOMO – or the fear of missing out – in the minds of buyers, who are worried prices might rise even further, Prakash Pahlajani, who runs Kumar Jewels, a family-owned business, told the BBC on a busy evening at his shop.

    “As a result, I have more customers this year,” Mr Pahlajani said.

    But with prices – gold is up 60% and silver 70% – shooting through the roof, jewellers are having to change tack to counter stagnant customer budgets.

    “People are not saying ‘I don’t want to buy’. Instead, they are saying, ‘I’ll buy a little less,” said Tanishq Gupta, another jeweller down the road from Mr Pahlajani’s shop.

    He said he’s had to be innovative and design pieces that look elaborate but have a reduced quantity of gold in them. A coin made of 250mg gold, which he sells for as low as $35, is now thinner but made to look as big as the heavier ones.

    Coins weighing a tenth of that, at 25mg, are also on offer in the market.

    Pushpinder Chauhan, another retailer in the area, said higher prices had also exacerbated the growing preference for lighter jewellery this year, “especially among younger buyers” who want pieces for everyday wear and not just special occasions.

    A set of gold coins of various weights and sizes being sold at a jewellery shop in Delhi, India.

    Retailers are selling gold coins weighing as low as 250mg to keep the demand going

    Several jewellers the BBC spoke to pointed to another clear trend – more customers were buying gold and silver for investment rather than jewellery this year, something that is also reflected in bullion market data.

    While gold jewellery continues to account for the largest share of India’s overall gold demand, the proportion driven by investment – primarily bars and coins – has been rising steadily, according to the World Gold Council (WGC).

    “Jewellery’s share declined to 64% in the second quarter of this year, from 80% in the same period in 2023, while investment demand increased from 19% to 35% over the same period,” Kavita Chacko, the council’s research head, told the BBC.

    A lot of that demand is also being fed by investment in exchange-traded funds (ETFs) or digital gold, where September marked record high inflows.

    ETF assets under management have surged by over 70% this year.

    Besides retail demand, gold prices are also being significantly influenced by India’s central bank, with the metal’s share in its foreign exchange reserves rising from 9% to 14% in 2025, according to WGC.

    In fact, the Reserve Bank of India (RBI) has been “a major pillar of global gold demand over the past three years”, said Kaynat Chainwala who tracks commodities at Kotak Securities, a broking house.

    She said the RBI has been stocking up on gold in a bid to diversify its foreign exchange holdings, reduce its dependence on the dollar and provide stability during geopolitical stress.

    A display of jewellery made of gold and lab-grown diamonds at a shop in Delhi, India.

    Those in the business say there’s a clear shift in demand from heavier to lighter jewellery

    Going forward, with the festive and the wedding season under way, retail demand for gold and silver is expected to continue to hold up despite record-high prices, say experts.

    “The affluent classes will continue to buy, though it is a setback for lower income families,” said Madan Sabnavis, the chief economist at the state-run Bank of Baroda. “Demand will hold up in value terms, even though volumes will fall.”

    But some families have been totally priced out of the market.

    “I am now having to think a lot while buying – about whether to even get something,” Bhavna, who’s getting married in February, told the BBC outside Mr Pahlajani’s jewellery store.

    For the moment, she’s held off her purchases and is waiting for prices to fall a bit so that she can come back to finish her wedding shopping.

    NurPhoto via Getty Images People buy gold ornaments at a jewelry showroom during Dhanteras in Guwahati, India, on October 29, 2024. On Dhanteras, people traditionally buy precious metals like gold, silver, or even new utensils, as it is believed this brings wealth and good luck into the household.NurPhoto via Getty Images

    Many Hindus purchase gold and silver during Diwali for good luck and prosperity

    Such strong cultural affinity for physical gold, particularly jewellery, means the appetite for the noble metal is unlikely to be dented in the long term, despite the short-term moderation, say experts.

    This is especially true for a country where high gold holdings have given solid long-term returns, making many Indians affluent at a time when growth is stumbling and jobs are hard to come by.

    According to the US investment bank Morgan Stanley, Indian households held a staggering $3.8tn of gold, equivalent to 88.8% of the country’s GDP.

    “This implies a positive wealth effect on the household balance sheet, given the uptrend in gold prices,” Economists Upasana Chachra and Bani Gambhir wrote in a recent note, adding that Indian families are also benefitting from “cyclical factors of lower interest payments with monetary policy easing, and the positive impact on disposable income through direct and indirect tax cuts”.

    That’s not a bad start to the festive season, even though record prices may have taken some glitter off the precious metal.

    Follow BBC News India on Instagram, YouTube, X and Facebook.


    Continue Reading

  • Long-Term MANEUVER Trial Data Spotlight Durable Responses With Pimicotinib in TGCT

    Long-Term MANEUVER Trial Data Spotlight Durable Responses With Pimicotinib in TGCT

    Long-term data from the phase 3 MANUEVER trial (NCT05804045) demonstrated that treatment with pimicotinib (ABSK021) led to robust and durable responses in patients with tenosynovial giant cell tumor (TGCT).1

    Findings presented at the 2025 ESMO Congress showed that at a median follow-up of 435 days (range, 78-686; 14.3 months) and a data cutoff date of March 12, 2025, patients treated with pimicotinib from baseline (n = 63) achieved an overall response rate (ORR) of 76.2% (95% CI, 63.8%-86.0%) per blinded independent central review (BICR) by RECIST 1.1 criteria; the BICR-assessed ORR per tumor volume score (TVS) was 74.6% (95% CI, 62.1%-84.7%). Best responses per RECIST 1.1 criteria comprised complete response (6.3%), partial response (69.8%), stable disease (19.0%), progressive disease (0%), and not evaluable (4.8%).

    MANEUVER Trial Highlights

    • The MANEUVER trial evaluated pimicotinib in patients with unresectable TCGT.
    • The study previously met its primary end point, with pimicotinib generating an ORR of 54.0% vs 3.2% for placebo.
    • Long-term data showed patients treated with pimicotinib from baseline experienced durable and robust responses, with an ORR of 76.2%.

    The 6- and 12-month duration of response (DOR) rates per BICR assessment and RECIST 1.1 criteria were 98% (95% CI, 84%-100%) and 92% (95% CI, 70%-98%), respectively.

    “Pimicotinib offers an effective, convenient, and tolerable systemic treatment option for patients with TGCT, providing early and durable tumor response with sustained relief from pain and functional impairments,” lead study author Xiaohui Niu, MD, of the Department of Orthopaedic Oncology Surgery at Beijing Ji Shui Tan Hospital at Peking University in China, said during a presentation of the data.

    How Was the MANEUVER Trial Designed?

    MANEUVER was a global, randomized, double-blind, placebo-controlled study evaluating pimicotinib—a highly selective and potent, small molecule CSF-1R inhibitor—in patients at least 18 years of age with histologically confirmed, unresectable TGCT who had measurable disease per RECIST 1.1 criteria with at least 1 lesion measuring at least 2 cm. Patients also needed to have symptomatic disease due to active TGCT.

    The trial was double-blinded for the first 24 weeks, where patients were randomly assigned 2:1 to receive pimicotinib orally at 50 mg once per day (n = 63) or matched placebo (n = 31).

    Previously reported data showed the study met its primary end point at week 25, with pimicotinib generating an ORR of 54.0% compared with 3.2% for placebo (P <.0001).2

    After week 24, the trial entered its open-label extension period, where patients in the experimental arm continued to receive pimicotinib, and those in the placebo arm crossed over to receive the agent.1

    Along with the primary end point of ORR per RECIST 1.1 criteria at week 25, secondary end points included ORR by TVS at week 25; and mean change from baseline to week 25 in range of motion, pain, stiffness, and PROMIS-PF T-score.

    What Additional Data Were Reported at the 2025 ESMO Congress?

    Findings also showed that patients treated with pimicotinib experienced clinically meaningful improvements in all clinical outcome assessments with longer-term follow-up, with durable improvements lasting beyond 1 year. Additionally, patients in the placebo arm who crossed over to receive pimicotinib had an ORR by BICR of 64.5% per RECIST v1.1 and TVS criteria at a median follow-up of 260 days (range, 85-505).

    Regarding safety, the most common clinical adverse effects (AEs) reported in patients who received pimicotinib from baseline included pruritus (all-grade, 60.3%; grade 3/4, 3.2%), facial edema (49.2%; 0%), rash (38.1%; 6.3%), periorbital edema (36.5%; 0%), fatigue (28.6%; 0%), nausea (28.6%; 0%), and headache (25.4%; 0%).

    Laboratory AEs were composed of increased blood creatine phosphokinase levels (all-grade, 71.4%; grade 3/4, 15.9%), increased blood lactate dehydrogenase levels (57.1%; 0%), increased aspartate aminotransferase levels (55.6%; 0%), increased amylase levels (38.1%; 0%), increased alpha-HBDH levels (25.4%; 0%), increased lipase levels (27.0%; 3.2%), increased blood creatine kinase MB levels (20.6%; 0%), and increase alanine aminotransferase levels (22.2%; 0%).

    Disclosures: Niu did not list any conflicts of interest.

    References

    1. Niu X, Ravi V, Broto JM, et al. Extended efficacy and safety from the phase 3 MANEUVER trial of pimicotinib in patients with tenosynovial giant cell tumour. Presented at: 2025 ESMO Congress; October 17-21, 2025; Berlin, Germany. Abstract 2690.
    2. Pimicotinib significantly improved outcomes for patients with tenosynovial giant cell tumor in a global phase III trial. News release. Merck KGaA. November 12, 2024. Accessed October 17, 2025. https://www.businesswire.com/news/home/20241111864964/en/Pimicotinib-Significantly-Improved-Outcomes-for-Patients-with-Tenosynovial-Giant-Cell-Tumor-in-a-Global-Phase-III-Trial

    Continue Reading

  • Saudi Arabia eyes defence deal with US after signing pact with Pakistan: report

    Saudi Arabia eyes defence deal with US after signing pact with Pakistan: report



    US President Donald Trump speaks with Saudi Arabia’s Crown Prince Mohammed bin Salman…

    Continue Reading

  • Statement attributable to the Spokesperson for the Secretary-General – on the continued public accusations made by the Houthis against United Nations personnel in Yemen | Secretary-General

    The Secretary-General is gravely concerned by the continued public accusations made by the Houthis, including on 16 October by their leadership, against United Nations personnel in Yemen. He categorically rejects all such accusations. 

    The…

    Continue Reading

  • Statement attributable to the Spokesperson for the Secretary-General – on the continued public accusations made by the Houthis against United Nations personnel in Yemen | Secretary-General

    The Secretary-General is gravely concerned by the continued public accusations made by the Houthis, including on 16 October by their leadership, against United Nations personnel in Yemen. He categorically rejects all such accusations. 

    The…

    Continue Reading

  • Rare type of cancer is on the rise among young people

    Rare type of cancer is on the rise among young people

    Appendix cancer was once a medical oddity that most people never heard about. Today, reports are stacking up in younger adults, and doctors are trying to make sense of it.

    This cancer starts in the small pouch off the large intestine, and it often…

    Continue Reading

  • Immune Altering Drug Hits Cancer In Stomach

    Immune Altering Drug Hits Cancer In Stomach

    Working with an international team of collaborators, scientists at Columbia University have found a way to shift the balance of a type of white blood cell inside a stomach tumor, causing the immune system to…

    Continue Reading

  • How 79-year-old influencer lost 30kg and now has the bone density of a 20-year-old

    How 79-year-old influencer lost 30kg and now has the bone density of a 20-year-old

    Joan MacDonald is an unlikely influencer. At nearly 80 years of age, she has garnered 2 million followers on Instagram since she began posting on the platform almost a decade ago. During that time, she has transformed her life and her health. Now…

    Continue Reading

  • Best Of The Red Carpet

    Best Of The Red Carpet

    The Daytime Emmy Awards red carpet was rolled out today as stars of daytime television gathered at the Pasadena Civic Auditorium in Pasadena, California, to celebrate their achievements.

    Mario Lopez is set to host the ceremony, with a…

    Continue Reading